newsfilter
← Latest News
Business Wire·

BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA

Agreement provides for generic entry of innovative BTK inhibitor in 2037 BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235)), a global oncology company which intends to change its name to BeOne Medicines Ltd.,